Rıza Aytaç Çetinkaya1, Ercan Yenilmez1, Patrizio Petrone2,3, Soner Yılmaz4, Bayhan Bektöre5, Berksan Şimsek6, Tuğba Kula Atik7, Mustafa Özyurt8, Aytekin Ünlü9. 1. Department of Infectious Disease, Sultan Abdulhamid Han Training and Education Hospital, University of Health Science, Istanbul, Turkey. 2. Department of Surgery, NYU Winthrop Hospital, 222 Station Plaza North, Suite 603, Mineola, Long Island, NY, 11501, USA. patrizio.petrone@gmail.com. 3. New York Medical College, New York, USA. patrizio.petrone@gmail.com. 4. Blood and Training Center, Gulhane Training and Education Hospital, University of Health Science, Ankara, Turkey. 5. Department of Microbiology, Kars Harakani State Hospital, Kars, Turkey. 6. Department of Microbiology, Transfusion Center, Okmeydani Research and Training Hospital, Kasimpasa Campus, University of Health Sciences, Istanbul, Turkey. 7. Department of Microbiology, Transfusion Center, Balıkesir State Hospital, Balıkesir, Turkey. 8. Department of Microbiology, Bilim University, Istanbul, Turkey. 9. Department of War Surgery, Gulhane Training and Research Hospital, Ankara, Turkey.
Abstract
PURPOSE: Infected wounds, such as diabetic foot infections, are mostly polymicrobial and microorganisms have high resistance rates to antimicrobials. Infected wounds in diabetic patients have high cost, morbidity, and mortality rates. Based on these facts, there is a need for supportive localized treatment options such as platelet-rich plasma (PRP) implementations. Demonstrating the in vitro antimicrobial effect, our aim was to lead up to clinical trials of localized PRP implementations in infected wounds such as diabetic foot infections. In this study, we aimed to demonstrate the in vitro antibacterial activity of PRP against methicilin-resistant Staphylococcus aureus (MRSA) and three more multi-drug resistant bacteria species that are important and hard-to-treat in wound infections. MATERIALS AND METHODS: In vitro antimicrobial activity of autologous PRP, platelet-poor plasma (PPP), and phosphate-buffered saline (PBS) on methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus spp., extended spectrum beta lactamase producing Klebsiella pneumoniae, and carbapenem-resistant Pseudomonas aeruginosa was compared by assessment of bacterial growth on agar plates and antimicrobial susceptibility test results. RESULTS: When compared to control group, PRP and PPP significantly suppressed bacterial growth of MRSA, K. pneumoniae, and P. aeruginosa at 1st, 2nd, 5th, and 10th hours of incubation (p < 0.05). VRE was the only bacteria that PRP and PPP showed limited activity against. When compared to PPP, PRP showed higher activity against MRSA, K. pneumoniae, and P. aeruginosa. However, the differences between PRP and PPP were statistically significant only against MRSA and P. aeruginosa at the first hour of incubation. CONCLUSIONS: Emerging PRP and other platelet-derived products seem to be promising alternative tools besides antibiotic treatment, debridement, negative pressure wound therapy, hyperbaric oxygen therapy, and other treatment options for treating diabetic foot infections.
PURPOSE:Infected wounds, such as diabetic foot infections, are mostly polymicrobial and microorganisms have high resistance rates to antimicrobials. Infected wounds in diabeticpatients have high cost, morbidity, and mortality rates. Based on these facts, there is a need for supportive localized treatment options such as platelet-rich plasma (PRP) implementations. Demonstrating the in vitro antimicrobial effect, our aim was to lead up to clinical trials of localized PRP implementations in infected wounds such as diabetic foot infections. In this study, we aimed to demonstrate the in vitro antibacterial activity of PRP against methicilin-resistant Staphylococcus aureus (MRSA) and three more multi-drug resistant bacteria species that are important and hard-to-treat in wound infections. MATERIALS AND METHODS: In vitro antimicrobial activity of autologous PRP, platelet-poor plasma (PPP), and phosphate-buffered saline (PBS) on methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus spp., extended spectrum beta lactamase producing Klebsiella pneumoniae, and carbapenem-resistant Pseudomonas aeruginosa was compared by assessment of bacterial growth on agar plates and antimicrobial susceptibility test results. RESULTS: When compared to control group, PRP and PPP significantly suppressed bacterial growth of MRSA, K. pneumoniae, and P. aeruginosa at 1st, 2nd, 5th, and 10th hours of incubation (p < 0.05). VRE was the only bacteria that PRP and PPP showed limited activity against. When compared to PPP, PRP showed higher activity against MRSA, K. pneumoniae, and P. aeruginosa. However, the differences between PRP and PPP were statistically significant only against MRSA and P. aeruginosa at the first hour of incubation. CONCLUSIONS: Emerging PRP and other platelet-derived products seem to be promising alternative tools besides antibiotic treatment, debridement, negative pressure wound therapy, hyperbaric oxygen therapy, and other treatment options for treating diabetic foot infections.
Authors: Wenhai Zhang; Yue Guo; Mitchell Kuss; Wen Shi; Amy L Aldrich; Jason Untrauer; Tammy Kielian; Bin Duan Journal: Tissue Eng Part B Rev Date: 2019-05-15 Impact factor: 6.389
Authors: Vincenzo Davide Palumbo; Stefano Rizzuto; Giuseppe Damiano; Salvatore Fazzotta; Andrea Gottardo; Giuseppina Mazzola; Attilio Ignazio Lo Monte Journal: J Med Case Rep Date: 2021-02-18